{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:03:29Z","timestamp":1762247009903,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart &amp; Lung"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.hrtlng.2025.05.020","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T21:49:15Z","timestamp":1749160155000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term effectiveness of SGLT2 inhibitors in type 2 diabetes patients with myocardial injury: A population-based study"],"prefix":"10.1016","volume":"73","author":[{"given":"Matteo","family":"Ponzoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Rea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Barron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cantarutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hrtlng.2025.05.020_bib0001","first-page":"322","article-title":"SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain","volume":"10","author":"Rolek","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"39","key":"10.1016\/j.hrtlng.2025.05.020_bib0002","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hrtlng.2025.05.020_bib0003","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hrtlng.2025.05.020_bib0004","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hrtlng.2025.05.020_bib0005","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.hrtlng.2025.05.020_bib0006","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hrtlng.2025.05.020_bib0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hrtlng.2025.05.020_bib0008","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"37","key":"10.1016\/j.hrtlng.2025.05.020_bib0009","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.hrtlng.2025.05.020_bib0010","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ejhf.2971","article-title":"Real-world use of sodium\u2013glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the <scp>Swedish<\/scp>Heart Failure Registry","volume":"25","author":"Stolfo","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.hrtlng.2025.05.020_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13092625","article-title":"The COVID-19 pandemic was associated with a change in therapeutic management and mortality in heart failure patients","volume":"13","author":"Ponzoni","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.05.020_bib0012","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1345\/aph.1K671","article-title":"Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication","volume":"43","author":"Martin","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.hrtlng.2025.05.020_bib0013","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0706743718802809","article-title":"Adherence to and persistence with antidepressant medication during pregnancy: does it differ by the class of antidepressant medication prescribed?","volume":"64","author":"Adhikari","year":"2019","journal-title":"Can J Psychiatry"},{"issue":"12","key":"10.1016\/j.hrtlng.2025.05.020_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019503","article-title":"Developing and validating a novel multisource comorbidity score from administrative data: a large population-based cohort study from Italy","volume":"7","author":"Corrao","year":"2017","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.hrtlng.2025.05.020_bib0015","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hrtlng.2025.05.020_bib0016","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.05.020_bib0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.hrtlng.2025.05.020_bib0018","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","article-title":"Direct cardio-protection of dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling","volume":"43","author":"Lin","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.05.020_bib0019","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/FJC.0000000000001466","article-title":"SGLT2 Inhibitor-pretreated macrophage transplantation improves adverse ventricular remodeling after acute myocardial infarction","volume":"82","author":"Chen","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrtlng.2025.05.020_bib0020","article-title":"Dapagliflozin alleviates myocardial ischemia\/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrtlng.2025.05.020_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT Registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.hrtlng.2025.05.020_bib0022","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(20)30344-2","article-title":"Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial","volume":"8","author":"McGuire","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.hrtlng.2025.05.020_bib0023","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"issue":"16","key":"10.1016\/j.hrtlng.2025.05.020_bib0024","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1016\/j.hrtlng.2025.05.020_bib0025","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.05.020_bib0026","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.111.171074","article-title":"Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study","volume":"58","author":"van Onzenoort","year":"2011","journal-title":"Hypertension"}],"container-title":["Heart &amp; Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:54:19Z","timestamp":1762246459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956325001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"alternative-id":["S0147956325001293"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.05.020","relation":{},"ISSN":["0147-9563"],"issn-type":[{"type":"print","value":"0147-9563"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness of SGLT2 inhibitors in type 2 diabetes patients with myocardial injury: A population-based study","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}